-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
China Cell announced on the evening of April 21 that recently, China Cell Engineering, a holding subsidiary, has received the registration and marketing authorization for the company's research product bevacizumab injection (product code: SCT510) issued by the State Food and Drug Administration.
Bevacizumab injection (Product code: SCT510)
The SCT510 product is a recombinant humanized anti-VEGF monoclonal antibody injection independently developed by China Cell Engineering.
Recombinant Humanized Anti-VEGF Monoclonal Antibody Injection Bevacizumab (Avitin)
In recent years, more and more companies have entered the PD-1 field, and the track has become increasingly crowded
There are already more than 40 pharmaceutical companies in the PD-1 over 10 billion market that are vying to deploy 9 types of Roche, Qilu, Innovent, Boan, Shengdia, Bio-Tech, Hisun, TOYO and Shanghai Henlius
Bevacizumab Avastin (Bevacizumab) is a humanized monoclonal antibody IgG1 developed by Roche .
Roche Angiogenesis Inhibitors 2004
Due to a wide range of indications, it has excellent efficacy in many types of tumors
Until December 2019, the first bevacizumab biosimilar drug (Qilu Pharmaceutical-Ankea) was approved for marketing , and the sales in the first year (2020) after listing reached 1.
The first bevacizumab biosimilar drug (Qilu Pharma-Ankea) was approved to market with 6 models of 1.
When bevacizumab is not included in medical insurance, the price is about 5253 yuan/bottle
5253 yuan/bottle 1998 yuan/bottle 1934 yuan/bottle
After the domestic bevacizumab biosimilar was launched, Roche's Avastin was hit by similar products, and the market capacity began to shrink .
Roche's Avastin was hit by similar products, and the market capacity began to shrink by US$3.
Trastuzumab (Herceptin) Rituximab (Rituxan) $ 2.
From 2016 to 2021, the sales terminals of [bevacizumab] in domestic sample hospitals showed a steady growth trend 1.
(Source: Minet)
In terms of brand structure, the original manufacturers Roche and Qilu Pharmaceutical occupy an absolute position in the market, together accounting for more than 90% ; Qilu Pharmaceutical, as the first imitation, has stably controlled Roche with a 55.
90% of Roche and Qilu Pharmaceuticals are the first generic Qilu Pharmaceuticals, and they have stably controlled Roche with a 55.
(Source: Minet)
Although a number of companies have approved bevacizumab for the market, there is still a huge demand for such drugs in Chinese patients, and the bevacizumab market is expected to have greater room for growth
In addition, the indications of bevacizumab are also expanding.
Companies that are first approved for listing can undoubtedly gain more market share in the early stage, but pricing strategies, continuous research and development of indications, and national centralized procurement will all be influencing factors.
This is a race to see who starts early, and also Who has a strong future and chooses the right game
.
According to the Frost & Sullivan report, the market size of bevacizumab in China will increase to RMB 6.
4 billion in 2023 and RMB 9.
9 billion in 2030, and the market prospect is extremely broad
.
4 billion yuan in 2023 and 9.
9 billion yuan in 2030, and the market prospect is extremely broad
.
